Lobato EB

Language: English
References: 18
Page: 335-337
PDF size: 65.71 Kb.

Text Extraction

INTRODUCTION

Since the introduction of percutaneous transluminal coronary angioplasty (PTCA) by Gruntzig in 1977, major advancements have been made in the clinical practice of percutaneous coronary intervention (PCI).
Despite the widespread use of these devices, bare metal stents (BMS) have been associated with a 20-30% restenosis rate requiring reintervention. Restenosis occurs as a result of neointimal hyperplasia–growth of scar tissue within the stent–due to the proliferation and migration of vascular smooth muscle cells. This phenomenon is clinically evident within the first 6-9 months after stent placement, and occurs in response to strut-associated injury and inflammation.

REFERENCES

1. Serruys PW, Kutryk MJB, Ong ATL. Coronary-artery stents. N Engl J Med 2006;354:483-95.

2. Moliterno DJ. Healing Achiles–sirolimus versus paclitaxel. N Engl J Med 2005;353:724-6.

3. Arjomand H, Turi Z, McCormick D, et al. Percutaneous coronary intervention: historical perspecitves, current status, and future direction. Am Heart J 2003;146:787-96.

4. Gawaz M, Neumann FJ, Ott I, et al. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 1996;94:279-85.

5. Caramori PRA, Lima VC, Seidelin PH, et al. Long-term endothelial dysfunction after coronary stenting. J Am Coll Cardiol 1999;34:1675-9.

6. Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines On Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 2002;105:1257-67.

7. Wilson SH, Fasseas P, Orford JL, et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 2003;42:234-40.

8. Biondi-Zoccai GG, Agostoni P, Abbate A, et al. Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent controlled trials. Int J Cardiol 2005;100:119-23.

9. Sousa, JE, Costa, MA, Sousa AG, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003;107:381-3.

10. Hill RA, Dundar Y, Bakhai A, et al. Drug-eluting stents: an early systematic review to inform policy. Eur Heart J 2004;25:902-19.

11. Tsimikas S. Drug-eluting stents and late adverse clinical outcomes: lessons learned, lessons awaited. J Am Coll Cardiol 2006;47:2112-5.

12. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous interventions. The task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-47.

13. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcomes of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.

14. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-21.

15. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans. J Am Coll Cardiol 2006;48:193-202.

16. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2006;296:epublished December 5, 2006. Available at: http://jama.ama-assn.org/cgi/reprint/297.2.joc60179v1. Accessed December 7, 2006.

17. Ong ATL, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-92.

18. Ferrari E, Benhamou M, Cerboni P, et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005;45:456-9.